32212-31-0Relevant academic research and scientific papers
QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF
-
Page/Page column 150; 181; 125, (2022/02/06)
The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in particular for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds having Structure I arecapable of increasing the level of adipose triglyceride lipase (ATGL). Also provided is the process of preparing compounds having Structure I.
Identification of novel quinazolinedione derivatives as RORγt inverse agonist
Fukase, Yoshiyuki,Sato, Ayumu,Tomata, Yoshihide,Ochida, Atsuko,Kono, Mitsunori,Yonemori, Kazuko,Koga, Keiko,Okui, Toshitake,Yamasaki, Masashi,Fujitani, Yasushi,Nakagawa, Hideyuki,Koyama, Ryoukichi,Nakayama, Masaharu,Skene, Robert,Sang, Bi-Ching,Hoffman, Isaac,Shirai, Junya,Yamamoto, Satoshi
, p. 721 - 736 (2018/02/07)
Novel small molecules were synthesized and evaluated as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of inflammatory and autoimmune diseases. A hit compound, 1, was discovered by high-throughput screeni
HETEROCYCLIC COMPOUND
-
Paragraph 0958, (2016/03/18)
The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.
